Pfizer (PFE) Gross Margin (2009 - 2026)
Pfizer (PFE) reported Gross Margin of 51.69% for Q1 2026, down 1705.0% year-over-year from 3.22% in Q1 2025, and down 173.87% quarter-over-quarter from 69.97% in Q4 2025.
Pfizer (PFE) Gross Margin (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of Gross Margin data on file, last reported at 51.69% in Q1 2026.
- Gross Margin for Q1 2026 came in at 51.69%, down 1705.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 31.46% (down 2040.0% YoY), and the FY2025 annual result was 74.33%, up 18714.0% from the prior year.
- Gross Margin eased to 51.69% in Q1 2026 per PFE's latest filing, from 69.97% in the prior quarter.
- Over five years, Gross Margin peaked at 77.29% in Q1 2024 and troughed at 1090.72% in Q3 2024.
- A 5-year average of 100.7% and a median of 34.64% in 2025 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin plunged 62726 bps in 2024, then surged 100917 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 73.22% in 2022, then sank by 264 bps to 120.24% in 2023, then plunged by 807 bps to 1090.72% in 2024, then jumped by 106 bps to 69.97% in 2025, then sank by 174 bps to 51.69% in 2026.
- Business Quant data shows PFE's Gross Margin at 51.69% in Q1 2026, 69.97% in Q4 2025, and 81.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 70.22% |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -51.69% |
| Dec 31, 2025 | 69.97% |
| Sep 28, 2025 | -81.55% |
| Jun 29, 2025 | -66.21% |
| Mar 30, 2025 | -34.64% |
| Sep 29, 2024 | -1,090.72% |
| Jun 30, 2024 | 75.16% |
| Mar 31, 2024 | 77.29% |
| Dec 31, 2023 | -120.24% |
| Oct 1, 2023 | -463.47% |
| Jul 2, 2023 | 7.25% |
| Apr 2, 2023 | -34.71% |
| Oct 2, 2022 | 73.22% |
| Jul 3, 2022 | 68.83% |
| Apr 3, 2022 | 61.09% |
| Oct 3, 2021 | 58.68% |
| Jul 4, 2021 | 62.98% |
| Apr 4, 2021 | 71.36% |
| Sep 27, 2020 | 80.47% |
| Jun 28, 2020 | 81.49% |